Arcus Biosciences Net Worth
Arcus Biosciences Net Worth Breakdown | RCUS |
Arcus Biosciences Net Worth Analysis
Arcus Biosciences' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Arcus Biosciences' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Arcus Biosciences' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Arcus Biosciences' net worth analysis. One common approach is to calculate Arcus Biosciences' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Arcus Biosciences' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Arcus Biosciences' net worth. This approach calculates the present value of Arcus Biosciences' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Arcus Biosciences' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Arcus Biosciences' net worth. This involves comparing Arcus Biosciences' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Arcus Biosciences' net worth relative to its peers.
Enterprise Value |
|
To determine if Arcus Biosciences is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Arcus Biosciences' net worth research are outlined below:
| Arcus Biosciences had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 258 M. Net Loss for the year was (283 M) with loss before overhead, payroll, taxes, and interest of (320 M). | |
| Arcus Biosciences currently holds about 1.05 B in cash with (170 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 14.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 65.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Arcus Biosciences Quemliclustat Receives Orphan Drug Designation for Pancreatic Cancer |
Arcus Biosciences uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Arcus Biosciences. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Arcus Biosciences' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Arcus Biosciences Target Price Consensus
Arcus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Arcus Biosciences' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 13 | Strong Buy |
Most Arcus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Arcus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Arcus Biosciences, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationArcus Biosciences Target Price Projection
Arcus Biosciences' current and average target prices are 9.15 and 28.18, respectively. The current price of Arcus Biosciences is the price at which Arcus Biosciences is currently trading. On the other hand, Arcus Biosciences' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Arcus Biosciences Market Quote on 22nd of July 2025
Target Price
Analyst Consensus On Arcus Biosciences Target Price
Know Arcus Biosciences' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Arcus Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Arcus Biosciences backward and forwards among themselves. Arcus Biosciences' institutional investor refers to the entity that pools money to purchase Arcus Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Parkman Healthcare Partners Llc | 2025-03-31 | 1.2 M | Millennium Management Llc | 2025-03-31 | 1.2 M | Ra Capital Management, Llc | 2025-03-31 | 1.1 M | Wellington Management Company Llp | 2025-03-31 | 1.1 M | Sofinnova Ventures | 2025-03-31 | 1 M | Jacobs Levy Equity Management, Inc. | 2025-03-31 | 972.2 K | Goldman Sachs Group Inc | 2025-03-31 | 914.2 K | Decheng Capital Llc | 2025-03-31 | 808.8 K | Morgan Stanley - Brokerage Accounts | 2025-03-31 | 787.1 K | Blackrock Inc | 2025-03-31 | 10.9 M | Vanguard Group Inc | 2025-03-31 | 6.7 M |
Follow Arcus Biosciences' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 980.5 M.Market Cap |
|
Project Arcus Biosciences' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.25) | (0.26) | |
| Return On Capital Employed | (0.36) | (0.37) | |
| Return On Assets | (0.25) | (0.26) | |
| Return On Equity | (0.58) | (0.61) |
When accessing Arcus Biosciences' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Arcus Biosciences' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Arcus Biosciences' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Arcus Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arcus Biosciences. Check Arcus Biosciences' Beneish M Score to see the likelihood of Arcus Biosciences' management manipulating its earnings.
Evaluate Arcus Biosciences' management efficiency
Arcus Biosciences has return on total asset (ROA) of (0.2225) % which means that it has lost $0.2225 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6317) %, meaning that it created substantial loss on money invested by shareholders. Arcus Biosciences' management efficiency ratios could be used to measure how well Arcus Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.26 in 2025. Return On Capital Employed is likely to drop to -0.37 in 2025. At this time, Arcus Biosciences' Net Tangible Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 204.6 M in 2025, whereas Other Assets are likely to drop slightly above 8.5 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 5.38 | 5.35 | |
| Tangible Book Value Per Share | 5.38 | 5.35 | |
| Enterprise Value Over EBITDA | (4.67) | (4.44) | |
| Price Book Value Ratio | 2.77 | 3.36 | |
| Enterprise Value Multiple | (4.67) | (4.44) | |
| Price Fair Value | 2.77 | 3.36 | |
| Enterprise Value | 2.5 B | 2.6 B |
Arcus Biosciences benefits from a management team that prioritizes both innovation and efficiency. We analyze these priorities to gauge the stock's future performance.
Enterprise Value Revenue 0.2259 | Revenue | Quarterly Revenue Growth (0.81) | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Arcus Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Arcus Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Arcus Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Arcus Biosciences Corporate Filings
| 15th of July 2025 Other Reports | ViewVerify | |
8K | 12th of June 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 13th of May 2025 Other Reports | ViewVerify | |
| 22nd of April 2025 Other Reports | ViewVerify |
Arcus Biosciences Earnings Estimation Breakdown
The calculation of Arcus Biosciences' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Arcus Biosciences is estimated to be -1.190425 with the future projection ranging from a low of -1.26 to a high of -1.13. Please be aware that this consensus of annual earnings estimates for Arcus Biosciences is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.26 Lowest | Expected EPS | -1.13 Highest |
Arcus Biosciences Earnings Projection Consensus
Suppose the current estimates of Arcus Biosciences' value are higher than the current market price of the Arcus Biosciences stock. In this case, investors may conclude that Arcus Biosciences is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Arcus Biosciences' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 13 | 78.45% | 0.0 | -1.190425 | -4.23 |
Arcus Biosciences Earnings per Share Projection vs Actual
Actual Earning per Share of Arcus Biosciences refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Arcus Biosciences predict the company's earnings will be in the future. The higher the earnings per share of Arcus Biosciences, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Arcus Biosciences Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Arcus Biosciences, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Arcus Biosciences should always be considered in relation to other companies to make a more educated investment decision.Arcus Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Arcus Biosciences' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
null | null | null | null | null | 0 | ||
null | null | null | null | null | 0 | ||
2025-05-06 | 2025-03-31 | -0.93 | -1.14 | -0.21 | 22 | ||
2025-02-19 | 2024-12-31 | -1.2031 | -1.03 | 0.1731 | 14 | ||
2024-11-06 | 2024-09-30 | -1.06 | -1.0 | 0.06 | 5 | ||
2024-08-08 | 2024-06-30 | -1.1 | -1.02 | 0.08 | 7 | ||
2024-05-08 | 2024-03-31 | -0.95 | -0.05 | 0.9 | 94 | ||
2024-02-21 | 2023-12-31 | -1.02 | -1.08 | -0.06 | 5 | ||
2023-11-07 | 2023-09-30 | -1.13 | -0.94 | 0.19 | 16 | ||
2023-08-07 | 2023-06-30 | -1.1 | -1.04 | 0.06 | 5 | ||
2023-05-09 | 2023-03-31 | -1.16 | -1.09 | 0.07 | 6 | ||
2023-02-28 | 2022-12-31 | -1.07 | -0.93 | 0.14 | 13 | ||
2022-11-02 | 2022-09-30 | -1.04 | -0.9 | 0.14 | 13 | ||
2022-08-03 | 2022-06-30 | -0.94 | -0.93 | 0.01 | 1 | ||
2022-05-09 | 2022-03-31 | -0.86 | -0.96 | -0.1 | 11 | ||
2022-02-23 | 2021-12-31 | -0.74 | 3.71 | 4.45 | 601 | ||
2021-11-08 | 2021-09-30 | -1.08 | -1.11 | -0.03 | 2 | ||
2021-08-05 | 2021-06-30 | -0.87 | -1.09 | -0.22 | 25 | ||
2021-05-05 | 2021-03-31 | -0.83 | -1.08 | -0.25 | 30 | ||
2021-02-24 | 2020-12-31 | -0.75 | -0.82 | -0.07 | 9 | ||
2020-11-05 | 2020-09-30 | 0.05 | 0.03 | -0.02 | 40 | ||
2020-08-06 | 2020-06-30 | -0.61 | -0.93 | -0.32 | 52 | ||
2020-05-05 | 2020-03-31 | -0.56 | -0.63 | -0.07 | 12 | ||
2020-03-05 | 2019-12-31 | -0.51 | -0.38 | 0.13 | 25 | ||
2019-11-05 | 2019-09-30 | -0.49 | -0.51 | -0.02 | 4 | ||
2019-08-06 | 2019-06-30 | -0.4 | -0.64 | -0.24 | 60 | ||
2019-05-02 | 2019-03-31 | -0.35 | -0.41 | -0.06 | 17 | ||
2019-03-05 | 2018-12-31 | -0.44 | -0.28 | 0.16 | 36 | ||
2018-11-08 | 2018-09-30 | -0.38 | -0.25 | 0.13 | 34 | ||
2018-08-06 | 2018-06-30 | -0.4 | -0.32 | 0.08 | 20 | ||
2018-05-09 | 2018-03-31 | -0.88 | -1.37 | -0.49 | 55 | ||
2018-03-16 | 2017-12-31 | 0 | -0.38 | -0.38 | 0 | ||
2017-05-04 | 2017-03-31 | 0 | -0.17 | -0.17 | 0 |
Arcus Biosciences Corporate Directors
| Patrick Machado | Independent Director | Profile | |
| Antoni Ribas | Independent Director | Profile | |
| Andrew Perlman | Independent Director | Profile | |
| Yasunori Kaneko | Lead Independent Director | Profile |
Additional Tools for Arcus Stock Analysis
When running Arcus Biosciences' price analysis, check to measure Arcus Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcus Biosciences is operating at the current time. Most of Arcus Biosciences' value examination focuses on studying past and present price action to predict the probability of Arcus Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcus Biosciences' price. Additionally, you may evaluate how the addition of Arcus Biosciences to your portfolios can decrease your overall portfolio volatility.